---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-096171"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:56:10.826100+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Achieve Life Sciences Q2 net loss $8.5M; FDA Breakthrough Therapy for cytisinicline vaping cessation

## Summary
- Q2 net loss $8.5M vs $8.0M prior year; cash & equivalents $61.3M as of June 30, 2024.
- FDA granted Breakthrough Therapy designation for cytisinicline for nicotine e-cigarette cessation; no FDA-approved treatments exist.
- Refinanced up to $20M loan with SVB; maturity extended to Dec 1, 2027 from Aug 1, 2024.
- Initiated ORCA-OL trial for long-term cytisinicline exposure; over 50% of 650 participants enrolled.
- Included in Russell 3000 and Russell Microcap indexes effective July 1, 2024.

## SEC filing metadata
- accession: 0000950170-24-096171
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000095017024096171/0000950170-24-096171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000095017024096171/achv-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-096171
- JSON: https://secwatch.observer/filing/0000950170-24-096171.json
- Plain text: https://secwatch.observer/filing/0000950170-24-096171.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.